The Clinicail Efficacy Observation In Treatment S Tabe Stage COPD(Lung And Kidney Qi Deficiency And Blood Stasis Syndrome) With Yiqi Bushen Huoxue Prescription

Objective;Observation of Yiqi Bushen Huoxue on stable stageCOPD (lung and kidney Qi and blood stasis syndrome) clinical symptoms, lung function and peripheral blood CD4+> CD8+ and CD4+/ CD8+effects, to evaluate the clinical efficacy and safety.Methods:70 patients met the inclusion criteria selected stable stage COPD using random number table, patients were randomly divided into test group-of 35 patients in the control group of 35 patients. The control group was only given the basic treatment of Western Medicine (Shah Mette Lo fluticasone propionate, commodity name Shu Lidie), The test group was given basic treatment and Yiqi Bushen Huoxue prescription. Then collect data and study the changes of clinical signs,symptoms,lung function index (FEV1%Pred、 FEV1/FVC), CD4+、CD8+ and CD4+/ CD8+before and after the treatment.Results:1.Yiqi Bushen Huoxue prescription in the treatment of stable COPD (lung and kidney qi deficiency and blood stasis syndrome) patients, can significantly improved the clinical symptoms, the treatment group, the total efficiency in 87.50%, total effective rate was 54.55% in the control group, two groups compared P< 0.05, with statistical significance.2. After treatment pulmonary function (FEV1% predicted, FEV1/FVC%) than before treatment has increased in value, but not statistically significant (P> 0.05). Comparison between the two groups after the treatment was not statistically significant.3. After treatment, the test group T lymphocytes in blood serum CD4+-. CD4+/ CD8+increased before treatment, CD8+ reduction, the control group had no significant change compared with the previous treatment, more statistically significant (P<0.05) between groups.4. There was no obvious change in the safety index before and after the treatment, the patients had no adverse reaction.Conclusions:1.Yiqi Bushen Huoxue prescription can improve the clinical signs of stable stage COPD(deficiency of lung and kidney Qi and blood stasis syndrome) patients.2. Yiqi Bushen Huoxue prescription on stable stage COPD (deficiency of lung and kidney Qi and blood stasis syndrome) patients have improved lung function, but not obvious.3.Yiqi Bushen Huoxue prescription can increase CD4+ and CD4+/ CD8+ and reduce CD8+, regulate immunities of stable stage COPD(deficiency of lung and kidney Qi and blood stasis syndrome) patients.4. The clinical application of COPD stable period (deficiency of lung and kidney Qi and blood stasis syndrome) for the treatment of Yiqi Bushen Huoxue prescription is safe and effective.